Sofia Carlsson
Jag är epidemiolog med ett starkt intresse för LADA (latent autoimmun diabetes hos vuxna), vuxendebuterande typ 1-diabetes och tidigt debuterande typ 2-diabetes. Min forskning syftar till att öka kuns
Om mig
Min forskning syftar till att öka kunskapen om orsaker till och konsekvenser av diabetes, med särskilt fokus på underutforskade former såsom LADA (latent autoimmun diabetes hos vuxna), vuxendebuterande typ 1-diabetes och tidigt debuterande typ 2-diabetes.
Forskningsbeskrivning
Mitt arbete syftar till att öka kunskapen om orsaker och konsekvenser av autoimmun diabetes hos vuxna, inklusive både LADA (latent autoimmun diabetes hos vuxna) och typ 1-diabetes, samt tidigt debuterande typ 2-diabetes. En viktig hörnsten i detta arbete är ESTRID-studien (epidemiologisk studie av riskfaktorer för LADA och typ 2-diabetes) https://ki.se/imm/forskning-vid-imm/enheter-vid-imm/enheten-for-epidemiologi/estrid, en pågående multicenterstudie som bedrivs vid IMM. ESTRID är den hittills största och mest detaljerade studien av LADA och erbjuder unika möjligheter att studera betydelsen av både miljöfaktorer och genetisk sårbarhet för sjukdomens insjuknande och prognos.
Utöver detta använder vi nationella registerdata och kombinerar traditionella kohortdesigner med familjebaserade studiedesigner för att stärka kausala tolkningar. Det övergripande målet med min forskning är att identifiera modifierbara riskfaktorer som kan användas för att förebygga LADA, typ 1-diabetes och tidigt debuterande typ 2-diabetes, samt att identifiera faktorer som bidrar till ogynnsam prognos för att möjliggöra effektiv sekundärprevention.
Undervisning
Jag har mer än 15 års erfarenhet av undervisning i epidemiologiska metoder (över 1 000 undervisningstimmar) vid Karolinska Institutet, både på grund- och avancerad nivå. Jag var kursansvarig för en fem veckor lång kurs i epidemiologiska metoder inom masterprogrammet i folkhälsovetenskap vid KI under perioden 2013–2022.
Artiklar
- Article: JOURNAL OF AUTOIMMUNITY. 2026;161:103576Sorgjerd EP; Hals IK; Lonnum BEE; Edstorp J; Ahlqvist E; Carlsson S; Grill V
- Article: NPJ PARKINSONS DISEASE. 2026;12(1):127Vincze K; Szwajda A; Ploner A; Karlsson R; Kang X; Tang B; Qin C; Domenighetti C; Sugier P-E; Ashok Kumar Sreelatha A; Schulte C; Portugal B; May P; Bobbili DR; Radivojkov-Blagojevic M; Lichtner P; Singleton AB; Hernandez DG; Edsall C; Mellick GD; Zimprich A; Pirker W; Rogaeva E; Lang AE; Koks S; Taba P; Lesage S; Brice A; Corvol J-C; Chartier-Harlin M-C; Mutez E; Brockmann K; Deutschlander AB; Burbulla LF; Hadjigeorgiou GM; Dardiotis E; Stefanis L; Simitsi AM; Valente EM; Petrucci S; Straniero L; Zecchinelli A; Pezzoli G; Brighina L; Ferrarese C; Annesi G; Quattrone A; Gagliardi M; Matsuo H; Nakayama A; Hattori N; Nishioka K; Chung SJ; Kim YJ; Kolber P; Van de Warrenburg BP; Bloem BR; Toft M; Pihlstrøm L; Correia Guedes L; Ferreira JJ; Bardien S; Carr J; Tolosa E; Ezquerra M; Pastor P; Ran C; Belin AC; Puschmann A; Clarke CE; Morrison KE; Tan M; Krainc D; Farrer MJ; Landoulsi Z; Kruger R; Gasser T; Elbaz A; Sharma M; Pedersen NL; Carlsson S; Hägg S; Wirdefeldt K; Comprehensive Unbiased Risk Factor Assessment for ; Domenighetti C; Sugier P-E; Ashok Kumar Sreelatha A; Schulte C; Portugal B; May P; Bobbili DR; Radivojkov-Blagojevic M; Lichtner P; Singleton AB; Hernandez DG; Edsall C; Mellick GD; Zimprich A; Pirker W; Rogaeva E; Lang AE; Koks S; Taba P; Lesage S; Brice A; Corvol J-C; Chartier-Harlin M-C; Mutez E; Brockmann K; Deutschlander AB; Burbulla LF; Hadjigeorgiou GM; Dardiotis E; Stefanis L; Simitsi AM; Valente EM; Petrucci S; Straniero L; Zecchinelli A; Pezzoli G; Brighina L; Ferrarese C; Annesi G; Quattrone A; Gagliardi M; Matsuo H; Nakayama A; Hattori N; Nishioka K; Chung SJ; Kim YJ; Kolber P; Van de Warrenburg BP; Bloem BR; Toft M; Pihlstrøm L; Correia Guedes L; Ferreira JJ; Bardien S; Carr J; Tolosa E; Ezquerra M; Pastor P; Ran C; Belin AC; Puschmann A; Clarke CE; Morrison KE; Tan M; Krainc D; Farrer MJ; Landoulsi Z; Kruger R; Gasser T; Elbaz A; Sharma M; Wirdefeldt K
- Article: DIABETOLOGIA. 2026;69(5):1226-1236Lampousi A-M; Zeng J; Lofvenborg JE; Carlsson S; Ludvigsson J
- Article: CANCERS. 2026;18(9):1428Zhang Z; Carlsson S; Hammar N; Acedo P; Russell B; Kordasti S; Sarker D; Hemelrijck MV; Santaolalla A
- Article: LANCET DIABETES & ENDOCRINOLOGY. 2026;14(3):223-232Bjarko VV; Wolford BN; Haug EB; Stene LC; Carlsson S; Langhammer A; Birkeland KI; Berg TJ; Sorgjerd EP; Lyssenko V; Brumpton BM; Vie GA; Asvold BO
- Article: METABOLOGIA. 2026;2(1):2Keysendal E; Carlsson S; Lampousi A-M; Hampe CS; Huerta JM; Kerrison N; Nilsson PM; Pala V; Schulze MB; Sharp SJ; Rolandsson O; Wareham NJ
- Article: EUROPEAN JOURNAL OF PUBLIC HEALTH. 2025;35(6):1258-1263Carlsson S; Andersson T; Jansson S; Nystrom T; Rolandsson O; Wei Y
- Article: CELL REPORTS MEDICINE. 2025;6(11):102454Zhao A; Wei Y; Kontidou E; Mahdi A; Jannig PR; Torstensson S; Jiang H; Larsson A; Collado A; Humoud R; Grunler J; Ersga D; Esen BO; Zheng X; Lu H; Lindgren E; Risal S; Zhao J; Stener-Victorin E; Sorensen HT; Pedersen L; Pernow J; Zhou Z; Carlsson S; Catrina S-B; Deng Q
- Article: CLINICAL NUTRITION. 2025;54:153-161Lampousi A-M; Ahlqvist E; Alfredsson L; Edstorp J; Di Giuseppe D; Grill V; Lofvenborg JE; Padyukov L; Tuomi T; Asvold BO; Carlsson S
- Article: EUROPEAN HEART JOURNAL. 2025;46(38):3776-3786Wei Y; Andersson T; Tuomi T; Nystrom T; Carlsson S
- Article: DIABETIC MEDICINE. 2025;42(10):e70106Riise HKR; Haugstvedt A; Igland J; Wilhelmsen-Langeland A; Softeland E; Hermann M; Carlsson S; Skinner TC; Asvold BO; Iversen MM
- Article: EUROPEAN JOURNAL OF EPIDEMIOLOGY. 2025;40(7):845-857Amadou C; Wei Y; Tuomi T; Feychting M; Carlsson S
- Article: NATURE COMMUNICATIONS. 2025;16(1):5327Wei Y; Andersson T; Liu S; Feychting M; Kuja-Halkola R; Carlsson S
- Article: NEUROLOGY. 2025;104(5):e213372Tomson T; Andersson T; Carlsson S; Sveinsson O
- Article: DIABETOLOGY & METABOLIC SYNDROME. 2025;17(1):62Riise HKR; Haugstvedt A; Igland J; Graue M; Softeland E; Hermann M; Carlsson S; Skinner TC; Asvold BO; Iversen MM
- Article: DIABETOLOGIA. 2025;68(2):331-341Santoso C; Wei Y; Ahlqvist E; Tuomi T; Carlsson S
- Article: DIABETOLOGIA. 2025;68(1):69-81Edstorp J; Rossides M; Ahlqvist E; Alfredsson L; Askling J; Di Giuseppe D; Grill V; Sorgjerd EP; Tuomi T; Asvold BO; Carlsson S
- Article: EPILEPSY & BEHAVIOR. 2024;161:110106Melin S; Tomson T; Sveinsson O; Andersson T; Carlsson S; Rück C; Wirdefeldt K
- Article: BMJ OPEN DIABETES RESEARCH & CARE. 2024;12(6):e004493Bjarko VV; Haug EB; Langhammer A; Ruiz PL-D; Carlsson S; Birkeland KI; Berg TJ; Sorgjerd EP; Lyssenko V; Asvold BO
- Article: LANCET REGIONAL HEALTH-EUROPE. 2024;46:101056Sun J; Yao J; Olen O; Halfvarsson J; Bergman D; Ebrahimi F; Carlsson S; Ludvigsson J; Ludvigsson JF
- Visa fler
Alla övriga publikationer
- Review: DIABETOLOGIA. 2026;69(11):3131-3147Stener-Victorin E; Carlsson S; Hagstrom H; Taebnia N
- Review: DIABETOLOGIA. 2026;:1-20Carlsson S; Tuomi T; Lampousi A-M
- Review: SCANDINAVIAN JOURNAL OF PUBLIC HEALTH. 2025;54(8):942-953Carlsson S; Beck M; Bergstrom A; Dreij K; Ganguly K; Kippler M; Laguzzi F; Leander K; Lu D; Palmberg L; Upadhyay S; Zettergren A; Pershagen G
- Conference publication: DIABETOLOGIA. 2025;68:S4Wei Y; Nystrom T; Andersson T; Misra S; Tuomi T; Carlsson S
- Conference publication: DIABETOLOGIA. 2025;68:S186-S187Keysendal E; Ahlqvist E; Asvold BO; Edstorp J; Tuomi T; Bjarko VV; Carlsson S
- Review: ECLINICALMEDICINE. 2025;83:103222Zeng J; Beck M; Barouti AA; Loefvenborg JE; Carlsson S; Lampousi A-M
- Conference publication: EPILEPSIA. 2024;65:22Melin S; Tomson T; Sveinsson O; Carlsson S; Andersson T; Wirdefeldt K
- Conference publication: DIABETOLOGIA. 2024;67:S151-S152Lampousi A-M; Ahlqvist E; Alfredsson L; Askling J; Edstorp J; Di Giuseppe D; Grill V; Lofvenborg JE; Padyukov L; Sorgjerd EP; Tuomi T; Asvold BO; Carlsson S
- Conference publication: DIABETOLOGIA. 2024;67:S48Wei Y; Andersson T; Tuomi T; Nystrom T; Carlsson S
- Review: ADVANCES IN NUTRITION. 2024;15(5):100211Lampousi A-M; Lundberg T; Lofvenborg JE; Carlsson S
- Letter: DIABETOLOGIA. 2024;67(3):567-568Grill V; Sorgjerd E; Hals I; Carlsson S
- Conference publication: DIABETOLOGIA. 2023;66(SUPPL 1):S177-S178Edstorp J; Rossides M; Ahlqvist E; Alfredsson L; Rasouli B; Tuomi T; Carlsson S
- Conference publication: DIABETOLOGIA. 2023;66(SUPPL 1):S174-S175Lampousi A-M; Lundberg T; Lofvenborg JE; Carlsson S
- Conference publication: DIABETOLOGIA. 2023;66(SUPPL 1):S170Wei Y; Carlsson S
- Meeting abstract: LANCET GLOBAL HEALTH. 2023;11:S1Wei Y; Zhan Y; Carlsson S
- Conference publication: EPILEPSIA. 2022;63:151-152Melin S; Wirdefeldt K; Sveinsson O; Andersson T; Carlsson S; Tomson T
- Conference publication: DIABETOLOGIA. 2022;65(SUPPL 1):S114Wei Y; Ahlqvist E; Andersson T; Tuomi T; Carlsson S
- Conference publication: DIABETOLOGIA. 2022;65(SUPPL 1):S153Edstorp J; Ahlqvist E; Alfredsson L; Grill V; Rasouli B; Sorgjerd EP; Tuomi T; Asvold B; Carlsson S
- Conference publication: DIABETOLOGIA. 2022;65(SUPPL 1):S150-S151Lampousi A-M; Carlsson S; Lofvenborg JE
- Review: FRONTIERS IN ENDOCRINOLOGY. 2022;13:917850Carlsson S
- Visa fler
Forskningsbidrag
- TYP 2-DIABETES HOS UNGA, ETT VÄXANDE FOLKHÄLSOHOT MED TYDLIG SOCIAL GRADIENTFORTE1 januari 2026
- Swedish Research Council for Health Working Life and Welfare1 januari 2026 - 31 december 2029Research problem and specific questionsType 2 diabetes (T2D) is a common, chronic disease that increases the risk of cardiovascular disease and shortens life expectancy. T2D was formerly known as “old-age diabetes” but is now increasingly affecting adolescents and young adults (<40 years). In Sweden, the prevalence of early-onset T2D doubled between 2006 and 2021. The risk is highest among people with a foreign origin or low education and is increasing fastest in young women. This is an alarming trend because the earlier the disease develops, the higher the risk of serious complications and shortened life expectancy. Moreover, developing T2D at a young age may negatively affect family formation, professional life and pregnancy outcomes. Preventing early-onset T2D requires knowledge of the factors influencing the risk of developing the disease, and factors that increase the risk of complications and reduced life chances for those affected. International research on early-onset T2D is limited, and Swedish research almost non-existent. The aim of this project is to fill key knowledge gaps regarding the risk factors and consequences of early-onset T2D. Specifically, we will:RISK FACTORS: elucidate heritability and identify risk factors (pre- and perinatal factors, individual and contextual socioeconomic factors, ethnic origin, childhood/adolescent diseases, lifestyle factors).CONSEQUENCES: study mortality, cardiovascular disease, pregnancy outcomes and socio-economic consequences and identify prognostic factors (inadequate treatment, mental and somatic co-morbidity, glucose control and metabolic risk factors, lifestyle and socio-economic and demographic factors).Data and methodsWe have created a database consisting of the entire Swedish population and collected information from nine national registries over a 40-year period. This allows us to identify all those who developed T2D diabetes in Sweden since the 1990s, map exposures before diagnosis and follow their prognosis. We have identified kinship ties within the cohort and can thus combine traditional cohort design with family-based design and compare people who developed T2D with their siblings without diabetes with respect to possible risk factors and different health and socioeconomic outcomes. In this way, confounding can be minimized. We will also conduct focus group interviews with young people with T2D to generate hypotheses and deepen the interpretations of the results obtained.Societal relevance and utilisationT2D in young people is a significant public health threat, with a strong social gradient. The proposed project is the most comprehensive of its kind and has the potential to significantly increase knowledge about T2D and its determinants and consequences among young people in Sweden. The results can be used to identify vulnerable groups in need of targeted interventions, improve primary and secondary prevention and inform policy makers. Thereby, the study can contribute to improved public health and reduced health inequalities. The results will be communicated in the form of scientific articles and via reports and seminars aimed at authorities responsible for public health and care such as the Public Health Agency of Sweden and the National Board of Health and Welfare, as well as regional public health and healthcare planners and providers. We will also publish in professional journals to reach the clinical profession and communicate with patient organizations, such as the Swedish Diabetes Association and write articles in patient magazines.Plan for project realisationThe project is being carried out at Karolinska Institutet by a team with expertise in all aspects of the project (epidemiology, biostatistics, sociology, obstetrics, endocrinology and cardiology). Most of the data is available, and preliminary analyses show that the feasibility is high. Funding is sought for analysis, report writing, focus group interviews and communication of research results.
- Hur har den relativa betydelsen av arv och miljö vid utvecklandet av typ 1-diabetes förändrats under de senaste decennierna?Barndiabetesfonden1 maj 2025 - 30 april 2026
- Swedish Research Council1 januari 2023 - 31 december 2026Diabetes is a chronic disease affecting 1/5 swedes during their lifetime, associated with CVD and reduced life expectancy. With a finer classification of diabetes, opportunities arise for better assessment of factors influencing onset and prognosis, which may lead to improved prevention. This project involves subtypes within the broad categories T1D and T2DLADA– a common form of autoimmune diabetes, newly proposed subtypes of T2D- including a severe insulin resistant and a severe insulin deficient type, and adult onset T1D. We aim to provide new knowledge on the interplay environmental vs. genetic factors influences in the aetiology of these largely unexplored subtypes of diabetes. To this aim, we are conducting the world´s largest study of LADA, the ESTRID-study, with incident cases of LADA and T2D subtypes and clinical, genetic and environmental information. The Norwegian HUNT-study, European Epic-InterAct and UK biobank, which includes adult onset T1D, will be used for extensions and replication. We will use Mendelian Randomization design for causal inference. ESTRID and HUNT are linked to national registers allowing us to follow patients from diagnosis and assess the prognostic role of clinical, genetic and lifestyle factors. The aim is to identify factors increasing the risk of autoimmune diabetes in adults and different forms of T2D and factors contributing to poor prognosis. Such knowledge is central future efforts to prevent diabetes and its consequences.
- Swedish Research Council for Health Working Life and Welfare1 januari 2021 - 31 december 2024
- Infections, antibiotics, tobacco, genetic susceptibility and risk of Latent autoimmune diabetes in adults and type 2 diabetesNovo Nordisk Foundation1 januari 2020 - 31 december 2022
- Novo Nordisk Foundation1 januari 2019 - 31 december 2019
- Swedish Research Council1 januari 2019 - 31 december 2022
- Swedish Research Council for Health Working Life and Welfare1 januari 2019 - 31 december 2022
- LADA-LATENT AUTOIMMUNE DIABETES IN ADULTS, RISK FACTORS AND PROGNOSISNovo Nordisk Foundation1 januari 2018 - 31 december 2020
- Swedish Research Council for Health Working Life and Welfare1 oktober 2017 - 30 september 2021
- Novo Nordisk Foundation1 januari 2017 - 31 december 2017
- INFLUENCE OF DIET ON THE RISK OF LADA (LATENT AUTOIMMUNE DIABETES IN ADULTS) AND TYPE 2 DIABETESNovo Nordisk Foundation1 januari 2017 - 1 januari 2018
- Novo Nordisk Foundation1 januari 2016 - 31 december 2016
- Swedish Research Council for Health Working Life and Welfare1 december 2015 - 30 september 2016
- Swedish Research Council1 januari 2015 - 31 december 2018
- Swedish Research Council for Health Working Life and Welfare1 december 2012 - 31 december 2015
- Swedish Research Council1 januari 2010 - 31 december 2012
Anställningar
- Universitetslektor, Institutet för miljömedicin, Karolinska Institutet, 2015-
Examina och utbildning
- Docent, Epidemiologi, Karolinska Institutet, 2008
- MEDICINE DOKTORSEXAMEN, Institutet för miljömedicin, Karolinska Institutet, 2003
- LICENTIATEXAMEN, Institutet för miljömedicin, Karolinska Institutet, 1999